Statins and kidney disease: Is the study of heart and renal protection at the cutting edge of evidence?

Current Opinion in Cardiology

Volumn 27, Issue 4, 2012, Pages 429-440

  Jenkins, Mark ^a   Goldsmith, David ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

cardiovascular outcomes; chronic kidney disease; renal outcomes; statins

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; EZETIMIBE; FLUINDOSTATIN; FOSINOPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; DISEASE COURSE; DYSLIPIDEMIA; GLOMERULUS FILTRATION RATE; HEART PROTECTION; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER DISEASE; LIVER FUNCTION TEST; META ANALYSIS (TOPIC); MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT;

DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC; LIPID METABOLISM; PROTEINURIA; TREATMENT OUTCOME; UNITED STATES;

EID: 84862292906     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e328353b988     Document Type: Review

References (58)

1. Kwan B, Kronenberg F, Beddhu S, Cheung A. Lipoprotein metabolismand lipid management in chronic kidney disease. J Am Soc Nephrol 2007; 18:1246.
2. Weiner D, Sarnak M. Managing dyslipidemia in chronic kidney disease. J Gen Intern Med 2004; 19:1045.
3. Sniderman A, Solhpour A, Alam A, et al. Cardiovascular death in dialysis patients: Lessons we can learn from AURORA. Clin J Am Soc Nephrol 2010; 5:335-340.
4. Barter P, Ballantyne C, Carmena R, et al. ApoB versus cholesterol in estimating cardiovascular risk and in guiding therapy: Report of the thirtyperson/ten-country panel. J Intern Med 2006; 259:247-258.
5. Contois J, McConnell J, Sethi A, et al. Lipoproteins and Vascular Diseases Division Working Group on Best Practices: Apolipoprotein B and cardiovascular disease risk: Position statement from the AACC lipoproteins and vascular diseases division working groups on best practices. Clin Chem 2009; 55:407-419.
6. Schaeffner E, Kurth T, Curhan G, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003; 14:2084.
7. Muntner P, Hamm L, Kusek J, et al. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 2004; 140:9.
8. Contreras G, Hu B, Astor B, et al. Malnutrition-inflammation modifies the relationship of cholesterol with cardiovascular disease. J Am Soc Nephrol 2010; 21:2131.
9. Kilpatrick R, McAllister C, Kovesdy C, et al. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 2007; 18:293.
10. Liu Y, Coresh J, Eustace J, et al. Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA 2004; 291:451.
11. Chawla V, Greene T, Beck G, et al. Hyperlipidemia and long-term outcomes in nondiabetic chronic kidney disease. Clin J Am Soc Nephrol 2010; 5:1582
12. Kovesdy C, Anderson J, Kalantar-Zadeh K. Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: Affects of case mix and the malnutrition-inflammation-cachexia syndrome. J Am Soc Nephrol 2007; 18:304.
13. Miyamoto T, Carrero J, Stenvinkel P. Inflammation as a risk factor and target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens 2011; 20:662-668.
14. Baigent C, Landray M, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. Lancet 2011; 377:2181-2192.
15. Ridker P, MacFadyen J, Cressman M, Glynn R. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated highsensitivity C-reactive protein: A secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention - An Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol 2010; 55:1266-1273.
16. Keller D. Atorvastatin beats rosuvastatin in protecting kidneys in diabetic and nondiabetic patients. XLVII European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress.Medscape Medical News 2010. Published July 2, 2010. http://www.medscape.com/viewarticle/724583. [Accessed 27 Janaury 2012].
17. Kimura K, Shimano H, Yokote K, et al. Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease. Sub-Analysis of the LIVALO Effectiveness and Safety (LIVES) Study. J Atheroscler Thromb 2010; 17:601-609.
18. Ruggenenti P, Perna A, Tonelli M, et al. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-Angiotensin system blockade: The ESPLANADE trial. Clin J Am Soc Nephrol 2010; 5:1928.
19. Navaneethan S, Pansini F, Perkovic V, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009:CD007784.
20. Koren M, Davidson M, Wilson D, et al. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis 2009; 53:741-750.
21. Strippoli G, Navaneethan S, Johnson D, et al. Effects of statins in patients with chronic kidney disease: Meta-Analysis and meta-regression of randomised controlled trials. BMJ 2008; 336:645.
22. Rahman M, Baimbridge C, Davis B, et al. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Kidney Dis 2008; 52:412.
23. Shepherd J, Kastelein J, Bittner V, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: The Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2007; 2:1131.
24. Asselbergs F, Diercks G, Hillege H, et al. Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110:2809-2816.
25. Douglas K, O'Malley P, Jackson J. Meta-Analysis: The effect of statins on albuminuria. Ann Intern Med 2006; 145:117.
26. Tonelli M, Isles C, Curhan G, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004; 110:1557-1563.
27. Athyros V, Mikhailidis D, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study. J Clin Pathol 2004; 57:728-734.
28. Tonelli M, Moyé L, Sacks F, et al. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003; 14:1605.
29. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 2003; 361:2005-2016.
30. Kalaitzidis R, Bakris G. Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease? Curr Opin Nephrol Hypertens 2009; 18:386-391.
31. De Zeeuw D. Targeting proteinuria as a valid surrogate for individualized kidney protective therapy. Am J Kidney Dis 2008; 51:713-716.
32. Alsheikh-Ali A, Ambrose M, Kuvin J, et al. The safety of rosuvastatin as used in common clinical practice: A postmarketing analysis. Circulation 2005; 111:3051.
33. Ozsoy R, Koopman M, Kastelein J, Arisz L. The acute effect of atorvastatin on proteinuria in patients with chronic glomerulonephritis. Clin Nephrol 2005; 63:245.
34. Atthobari J, Brantsma A, Gansevoort R, et al. The effect of statins on urinary albumin excretion and glomerular filtration rate: Results from both a randomized clinical trial and an observational cohort study. Nephrol Dial Transplant 2006; 21:3106.
35. De Zeeuw D. Prospective evaluation of proteinuria and renal function in nondiabetic patients with progressive renal disease. In: XLVII European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress, Munich, Germany. 25-28 June 2010.
36. Shepherd J, Kastelein J, Bittner V, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: The TNT (Treating to New Targets) study. J Am Coll Cardiol 2008; 51: 1448.
37. Sandhu S, Wiebe N, Fried L, Tonelli M. Statins for improving renal outcomes: A meta-Analysis. J Am Soc Nephrol 2006; 17:2006-2016.
38. Conley J, Olafsson A, Djamali A. Do statins delay the incidence of ESRD in diabetic patients with moderate CKD? J Nephrol 2010; 23:321-327.
39. Afzali B, Haydar A, Vinen K, Goldsmith D. From Finland to fatland: Beneficial effects of statins for patients with chronic kidney disease. J Am Soc Nephrol 2004; 15:2161.
40. Ridker P, Danielson E, Fonseca F, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207.
41. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1381-1389.
42. Brugts J, Yetgin T, Hoeks S, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: Metaanalysis of randomised controlled trials. BMJ 2009; 338:2376.
43. Krane V, Winkler W, Drechsler C, et al. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus. Am J Kidney Dis 2009; 54:902-911.
44. Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing haemodialysis. N Engl J Med 2005; 353:238.
45. Fellström B, Jardine A. Schmieder R, for the AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360:1395-1407.
46. Holdaas H, Fellström B, Jardine A, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebocontrolled trial. Lancet 2003; 361:2024.
47. Szummer K, Lundman P, Jacobson S, et al. Association between statin treatment and outcome in relation to renal function in survivors of myocardial infarction. Kidney Int 2011; 79:997-1004.
48. Razavian M, Heeley E, Perkovic V, et al. Cardiovascular risk management in chronic kidney disease in general practice (the AusHEART study). Nephrol Dial Transplant 2011; 27:1396-1402.
49. K/DOQI Working Group. Managing Dyslipidaemia in Chronic Kidney Disease. Published 2003. http://www.kidney.org/professionals/kdoqi/guide lines-lipids/index.htm. [Accessed 20 Janaury 2012]
50. Hage F, Venkataraman R, Zoghbi G, et al. The scope of coronary heart disease in patients with chronic kidney disease. J Am Coll Cardiol 2009; 53:2129-2140.
51. Holdaas H, Holme I, Schmieder R, et al. Rosuvastatin in diabetic hemodialysis patients. J Am Soc Nephrol 2011; 22:1335-1341.
52. Soveri I, Holdaas H, Jardine A, et al. Renal transplant dysfunction-importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality. Nephrol Dial Transplant 2006; 21:2282-2289.
53. Baigent C, Landray M, Leaper C, et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis 2005; 45:473.
54. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: A posthoc analysis. Lancet 2010; 376:1916-1922.
55. Merck. New FDA approved labeling for Vytorin( (ezetimibe/simvastatin) includes results from the Study of Heart and Renal Protection (SHARP) in patients with moderate to severe chronic kidney disease [press release]. Published January 25, 2012. http://www.merck.com/newsroom/newsrelease-Archive/ prescription-medicine-news/2012-0125.html. [Accessed 26 January 2012]
56. Holt S, Goldsmith D. The Renal Association Guidelines on 'Cardiovascular Disease and CKD.' Published 2010. www.renal.org/Clinical/Guidelines Section. [Accessed 20 January 2012]
57. National Instititue for Health and Clinical Excellence. Chronic Kidney Disease Guideline. Published 2008. www.nice.org.uk/nicemedia/live/12069/42545/ 42545.doc. [Accessed 20 January 2012]
58. Wierzbicki AS. The ezetimibe Jonah: The trials and tribulations of an unlucky ug. Int J Clin Pract 2011; 65:1207-1208.